Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 860,059
  • Shares Outstanding, K 20,342
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -138 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.27
  • Price/Sales 8.66
  • Price/Cash Flow N/A
  • Price/Book 9.37

Options Overview Details

View History
  • Implied Volatility 99.97% (+1.46%)
  • Historical Volatility 83.92%
  • IV Percentile 30%
  • IV Rank 6.29%
  • IV High 620.58% on 04/16/25
  • IV Low 65.00% on 08/28/25
  • Expected Move (DTE 14) 4.65 (11.00%)
  • Put/Call Vol Ratio 0.80
  • Today's Volume 225
  • Volume Avg (30-Day) 1,862
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 23,931
  • Open Int (30-Day) 28,434
  • Expected Range 37.63 to 46.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.69
  • Number of Estimates 6
  • High Estimate -1.98
  • Low Estimate -3.68
  • Prior Year -2.25
  • Growth Rate Est. (year over year) -19.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.32 +2.32%
on 12/30/25
64.31 -34.26%
on 12/01/25
-22.93 (-35.16%)
since 11/28/25
3-Month
41.32 +2.32%
on 12/30/25
66.92 -36.82%
on 10/31/25
-14.62 (-25.69%)
since 09/30/25
52-Week
6.45 +555.50%
on 04/09/25
66.92 -36.82%
on 10/31/25
+28.12 (+198.59%)
since 12/30/24

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised...

NKTR : 42.28 (+0.91%)
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo

NKTR : 42.28 (+0.91%)
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will...

NKTR : 42.28 (+0.91%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified...

NKTR : 42.28 (+0.91%)
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma

NKTR : 42.28 (+0.91%)
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 42.28 (+0.91%)
Nektar Therapeutics Reports Third Quarter 2025 Financial Results

SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025.

NKTR : 42.28 (+0.91%)
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare...

NKTR : 42.28 (+0.91%)
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based...

NKTR : 42.28 (+0.91%)
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist...

NKTR : 42.28 (+0.91%)

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 43.55
2nd Resistance Point 43.01
1st Resistance Point 42.64
Last Price 42.28
1st Support Level 41.73
2nd Support Level 41.19
3rd Support Level 40.82

See More

52-Week High 66.92
Fibonacci 61.8% 43.82
Last Price 42.28
Fibonacci 50% 36.68
Fibonacci 38.2% 29.55
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar